company background image
MORF

Morphic Holding NasdaqGM:MORF Stock Report

Last Price

US$27.52

Market Cap

US$1.1b

7D

-3.7%

1Y

-39.1%

Updated

01 Dec, 2022

Data

Company Financials +
MORF fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

MORF Stock Overview

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer.

Morphic Holding, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Morphic Holding
Historical stock prices
Current Share PriceUS$27.52
52 Week HighUS$52.34
52 Week LowUS$19.23
Beta1.26
1 Month Change-1.75%
3 Month Change-5.10%
1 Year Change-39.13%
3 Year Change90.19%
5 Year Changen/a
Change since IPO52.89%

Recent News & Updates

What Does The Future Hold For Morphic Holding, Inc. (NASDAQ:MORF)? These Analysts Have Been Cutting Their Estimates

Nov 08
What Does The Future Hold For Morphic Holding, Inc. (NASDAQ:MORF)? These Analysts Have Been Cutting Their Estimates

Recent updates

What Does The Future Hold For Morphic Holding, Inc. (NASDAQ:MORF)? These Analysts Have Been Cutting Their Estimates

Nov 08
What Does The Future Hold For Morphic Holding, Inc. (NASDAQ:MORF)? These Analysts Have Been Cutting Their Estimates

Revenue Downgrade: Here's What Analysts Forecast For Morphic Holding, Inc. (NASDAQ:MORF)

May 06
Revenue Downgrade: Here's What Analysts Forecast For Morphic Holding, Inc. (NASDAQ:MORF)

Analyst Forecasts Just Became More Bearish On Morphic Holding, Inc. (NASDAQ:MORF)

Mar 01
Analyst Forecasts Just Became More Bearish On Morphic Holding, Inc. (NASDAQ:MORF)

Here's Why We're Not Too Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Situation

Feb 17
Here's Why We're Not Too Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Situation

We're Not Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn

Nov 03
We're Not Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn

Morphic Holding (NASDAQ:MORF) Is In A Strong Position To Grow Its Business

Aug 05
Morphic Holding (NASDAQ:MORF) Is In A Strong Position To Grow Its Business

Companies Like Morphic Holding (NASDAQ:MORF) Can Afford To Invest In Growth

Apr 05
Companies Like Morphic Holding (NASDAQ:MORF) Can Afford To Invest In Growth

Independent Director Vikas Goyal Just Bought A Handful Of Shares In Morphic Holding, Inc. (NASDAQ:MORF)

Mar 09
Independent Director Vikas Goyal Just Bought A Handful Of Shares In Morphic Holding, Inc. (NASDAQ:MORF)

Did Business Growth Power Morphic Holding's (NASDAQ:MORF) Share Price Gain of 126%?

Feb 24
Did Business Growth Power Morphic Holding's (NASDAQ:MORF) Share Price Gain of 126%?

How Many Morphic Holding, Inc. (NASDAQ:MORF) Shares Have Insiders Sold, In The Last Year?

Jan 20
How Many Morphic Holding, Inc. (NASDAQ:MORF) Shares Have Insiders Sold, In The Last Year?

Companies Like Morphic Holding (NASDAQ:MORF) Can Afford To Invest In Growth

Dec 16
Companies Like Morphic Holding (NASDAQ:MORF) Can Afford To Invest In Growth

Shareholder Returns

MORFUS BiotechsUS Market
7D-3.7%2.3%1.5%
1Y-39.1%-10.2%-14.8%

Return vs Industry: MORF underperformed the US Biotechs industry which returned -15.2% over the past year.

Return vs Market: MORF underperformed the US Market which returned -18.9% over the past year.

Price Volatility

Is MORF's price volatile compared to industry and market?
MORF volatility
MORF Average Weekly Movement8.9%
Biotechs Industry Average Movement11.2%
Market Average Movement7.4%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market3.3%

Stable Share Price: MORF is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: MORF's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2014103Praveen Tipirnenihttps://www.morphictx.com

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also developing avß6 for the treatment of fibrotic diseases, and avß8 to treat solid tumors, as well as various other products.

Morphic Holding, Inc. Fundamentals Summary

How do Morphic Holding's earnings and revenue compare to its market cap?
MORF fundamental statistics
Market CapUS$1.06b
Earnings (TTM)-US$56.07m
Revenue (TTM)US$74.23m

14.3x

P/S Ratio

-18.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MORF income statement (TTM)
RevenueUS$74.23m
Cost of RevenueUS$87.79m
Gross Profit-US$13.56m
Other ExpensesUS$42.51m
Earnings-US$56.07m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.45
Gross Margin-18.27%
Net Profit Margin-75.53%
Debt/Equity Ratio0%

How did MORF perform over the long term?

See historical performance and comparison